{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:17:05Z","timestamp":1793038625316,"version":"4.5.0"},"reference-count":411,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.pharmthera.2022.108301","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T19:12:24Z","timestamp":1666552344000},"page":"108301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises"],"prefix":"10.1016","volume":"240","author":[{"given":"I.","family":"Anestopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Tragkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Paraskevaidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tzika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mitsiogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Deligiorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Petrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.T.","family":"Trafalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Botaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Giatromanolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.I.","family":"Koukourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.I.","family":"Panayiotidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2022.108301_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0458-3","article-title":"The use of immunotherapy in the treatment of melanoma","volume":"10","author":"Achkar","year":"2017","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00173","article-title":"Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance","volume":"8","author":"Ahmed","year":"2018","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-med-111314-035900","article-title":"Epigenetic therapeutics: A new weapon in the war against cancer","volume":"67","author":"Ahuja","year":"2016","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy","volume":"40","author":"Al Emran","year":"2019","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0030","first-page":"1103","article-title":"BRAF in malignant melanoma progression and metastasis: potentials and challenges","volume":"10","author":"Alqathama","year":"2020","journal-title":"American Journal of Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I \u2013 Activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0040","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Current Biology: CB"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2014.09.005","article-title":"Epigenetic therapy as a novel approach in hepatocellular carcinoma","volume":"145","author":"Anestopoulos","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/1570180054038413","article-title":"Computational studies of 1-hydrazinophthalazine (hydralazine) as antineoplasic agent. docking studies on methyltransferase","volume":"2","author":"Angeles","year":"2005","journal-title":"Letters in Drug Design & Discovery"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0055","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatology Practical & Conceptual"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0060","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/carcin\/bgr138","article-title":"Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma","volume":"32","author":"Arab","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0065","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00394-017-1527-7","article-title":"Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells","volume":"57","author":"Arcidiacono","year":"2018","journal-title":"European Journal of Nutrition"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0070","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/jdv.12236","article-title":"Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015","volume":"28","author":"Arnold","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108301_bb0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40257-022-00681-4","article-title":"Long-term outcomes of immune checkpoint inhibition in metastatic melanoma","volume":"23","author":"Aroldi","year":"2022","journal-title":"American Journal of Clinical Dermatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108301_bb0080","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"The Lancet. Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108301_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0090","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/labinvest.2017.5","article-title":"Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing","volume":"97","author":"Babapoor","year":"2017","journal-title":"Laboratory Investigation; a Journal of Technical Methods and Pathology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108301_bb0095","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/onc.2013.588","article-title":"A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity","volume":"34","author":"Bajpe","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jcmm.12345","article-title":"HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis","volume":"19","author":"Balliu","year":"2015","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0110","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.1158\/0008-5472.CAN-03-3897","article-title":"Overexpression of histone deacetylase 1 confers resistance to sodium butyrate\u2013mediated apoptosis in melanoma cells through a p53-mediated pathway","volume":"64","author":"Bandyopadhyay","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221090306","article-title":"Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?","volume":"14","author":"Bari","year":"2022","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108301_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-018-0729-3","article-title":"The role of oncolytic viruses in the treatment of melanoma","volume":"20","author":"Bayan","year":"2018","journal-title":"Current Oncology Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0130","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-07-2912","article-title":"MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines","volume":"68","author":"Bemis","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0135","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1038\/sj.onc.1206446","article-title":"Human melanocyte senescence and melanoma susceptibility genes","volume":"22","author":"Bennett","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0140","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.devcel.2010.10.005","article-title":"Aberrant epigenetic landscape in cancer: How cellular identity goes awry","volume":"19","author":"Berdasco","year":"2010","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0145","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth","volume":"55","author":"Bergman","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0150","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immunity"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0155","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jmcb\/mju027","article-title":"Epigenetics of human melanoma: promises and challenges","volume":"6","author":"Besaratinia","year":"2014","journal-title":"Journal of Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0160","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-009-0420-3","article-title":"Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells","volume":"120","author":"Billam","year":"2010","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0165","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.det.2019.05.001","article-title":"Systemic therapies for advanced melanoma","volume":"37","author":"Bomar","year":"2019","journal-title":"Dermatologic Clinics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CMR.0b013e32834f6fbb","article-title":"MicroRNA regulation of melanoma progression","volume":"22","author":"Bonazzi","year":"2012","journal-title":"Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0175","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0180","doi-asserted-by":"crossref","first-page":"83155","DOI":"10.18632\/oncotarget.17950","article-title":"HDAC inhibitors enhance the immunotherapy response of melanoma cells","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0190","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/2159-8290.CD-15-1200","article-title":"In vivo genetic screens of patient-derived tumors revealed unexpected frailty of the transformed phenotype","volume":"6","author":"Bossi","year":"2016","journal-title":"Cancer Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108301_bb0195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0749.2005.00228.x","article-title":"Histone deacetylase inhibitors and malignant melanoma","volume":"18","author":"Boyle","year":"2005","journal-title":"Pigment Cell Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0205","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s40425-019-0745-3","article-title":"Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)","volume":"7","author":"Bretz","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-016-0283-5","article-title":"The quest for an effective and safe personalized cell therapy using epigenetic tools","volume":"8","author":"Brevini","year":"2016","journal-title":"Clinical Epigenetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4010-9","article-title":"Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma","volume":"18","author":"Budden","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-020-0228-x","article-title":"Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R","volume":"9","author":"Bugide","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0225","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/neuonc\/nor072","article-title":"AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas","volume":"13","author":"Bush","year":"2011","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0230","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.jid.2017.03.039","article-title":"MiR-200a regulates CDK4\/6 inhibitor effect by targeting CDK6 in metastatic melanoma","volume":"137","author":"Bustos","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14656566.2019.1694664","article-title":"An evaluation of encorafenib for the treatment of melanoma","volume":"21","author":"Carr","year":"2019","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0240","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1582-4934.2011.01464.x","article-title":"The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells","volume":"16","author":"Cellai","year":"2012","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0245","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature09806","article-title":"The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset","volume":"471","author":"Ceol","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108301_bb0250","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/17460441.2021.1942834","article-title":"Advances in the discovery and development of melanoma drug therapies","volume":"16","author":"Chanda","year":"2021","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bjc.2011.532","article-title":"Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide","volume":"106","author":"Chang","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0260","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.isci.2018.05.021","article-title":"Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma","volume":"4","author":"Chatterjee","year":"2018","journal-title":"IScience"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0265","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.seizure.2011.10.002","article-title":"Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy","volume":"21","author":"Chen","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0270","doi-asserted-by":"crossref","first-page":"11209","DOI":"10.1007\/s13277-016-4994-1","article-title":"DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines","volume":"37","author":"Chen","year":"2016","journal-title":"Tumor Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-biochem-103019-102815","article-title":"Role of mammalian DNA methyltransferases in development","volume":"89","author":"Chen","year":"2020","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0280","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0285","article-title":"Epigenetics regulates antitumor immunity in melanoma","volume":"13","author":"Chen","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2019.04.017","article-title":"Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors","volume":"173","author":"Cheng","year":"2019","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0295","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.036","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"169","author":"Chiappinelli","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0300","first-page":"917","article-title":"Effect of valproic acid on the proliferation and apoptosis of the human melanoma G-361 cell line","volume":"71","author":"Chodurek","year":"2014","journal-title":"Acta Poloniae Pharmaceutica"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0305","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1016\/j.bmcl.2012.09.093","article-title":"The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C6 position","volume":"22","author":"Choi","year":"2012","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0310","first-page":"4999","article-title":"Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)","volume":"19","author":"Cohen","year":"1999","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0315","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1755-148X.2011.00828.x","article-title":"DNA-methylation profiling distinguishes malignant melanomas from benign nevi","volume":"24","author":"Conway","year":"2011","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cbpa.2020.04.008","article-title":"Towards a more precise therapy in cancer: Exploring epigenetic complexity","volume":"57","author":"Coss\u00edo","year":"2020","journal-title":"Current Opinion in Chemical Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2006.09.028","article-title":"Non-coding RNAs: Lost in translation?","volume":"386","author":"Costa","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0330","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4065\/81.4.500","article-title":"Cutaneous malignant melanoma","volume":"81","author":"Cummins","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0335","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ccr.2011.10.014","article-title":"Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis","volume":"20","author":"Darido","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0340","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1126\/science.aam7304","article-title":"The cancer epigenome: Concepts, challenges, and therapeutic opportunities","volume":"355","author":"Dawson","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0345","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0350","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CMR.0000000000000141","article-title":"LINE-1 hypermethylation in peripheral blood of cutaneous melanoma patients is associated with metastasis","volume":"25","author":"de Ara\u00fajo","year":"2015","journal-title":"Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0355","first-page":"394","article-title":"Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma","volume":"179","author":"de Unamuno Bustos","year":"2018","journal-title":"The British Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0360","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/bmj.331.7518.698","article-title":"Melanoma incidence has risen in Europe","volume":"331","author":"de Vries","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0365","first-page":"499","article-title":"Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A\/J mice","volume":"23","author":"Desai","year":"2003","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0370","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.bmcl.2009.07.068","article-title":"SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors","volume":"20","author":"Desai","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0375","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.ymthe.2018.05.020","article-title":"Therapeutic silencing of miR-214 inhibits tumor progression in multiple mouse models","volume":"26","author":"Dettori","year":"2018","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0380","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1023\/A:1023267224819","article-title":"Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered","volume":"28","author":"Deutsch","year":"2003","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0385","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1158\/1078-0432.CCR-19-1335","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: The NIBIT-M4 clinical trial","volume":"25","author":"di Giacomo","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0390","doi-asserted-by":"crossref","first-page":"35374","DOI":"10.18632\/oncotarget.26244","article-title":"New insights in melanoma resistance to BRAF inhibitors: a role for microRNAs","volume":"9","author":"D\u00edaz-Mart\u00ednez","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108301_bb0395","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/0008-5472.CAN-17-1318","article-title":"miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma","volume":"78","author":"D\u00edaz-Mart\u00ednez","year":"2018","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2693-3","article-title":"Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity","volume":"16","author":"D\u00edaz-N\u00fa\u00f1ez","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0405","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Diederich","year":"2010","journal-title":"Journal of Biomedicine & Biotechnology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clinical Epigenetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0415","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"ImmunoTargets and Therapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0420","first-page":"OL1861","article-title":"Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice","volume":"59","author":"Dou","year":"2013","journal-title":"Cellular and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0425","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/annonc\/mdx040","article-title":"Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study","volume":"28","author":"Dr\u00e9no","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0430","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1517\/17425255.2014.947263","article-title":"Hydralazine-valproate: A repositioned drug combination for the epigenetic therapy of cancer","volume":"10","author":"Due\u00f1as-Gonzalez","year":"2014","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0435","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"The Lancet Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108301_bb0440","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0445","article-title":"COLUMBUS 5-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"JCO2102659","author":"Dummer","year":"2022","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0450","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708446","article-title":"Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma","volume":"10","author":"Echevarr\u00eda-Vargas","year":"2018","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0460","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0465","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1016\/j.pharmthera.2022.108301_bb0470","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"33","key":"10.1016\/j.pharmthera.2022.108301_bb0475","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG\/KEYNOTE-054 Trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108301_bb0480","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0485","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/epi.09.33","article-title":"DNA hypomethylation in cancer cells","volume":"1","author":"Ehrlich","year":"2009","journal-title":"Epigenomics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013176","article-title":"MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion","volume":"5","author":"Elson-Schwab","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0495","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","article-title":"HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy","volume":"79","author":"Emmons","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0500","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: From the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Current Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0505","first-page":"118","article-title":"Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma","author":"Falahat","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0510","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/1541-7786.MCR-10-0511","article-title":"EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21\/CDKN1A expression","volume":"9","author":"Fan","year":"2011","journal-title":"Molecular Cancer Research"},{"issue":"13","key":"10.1016\/j.pharmthera.2022.108301_bb0515","doi-asserted-by":"crossref","first-page":"22262","DOI":"10.18632\/oncotarget.14763","article-title":"MicroRNAs in melanoma development and resistance to target therapy","volume":"8","author":"Fattore","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0520","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrc1279","article-title":"The history of cancer epigenetics","volume":"4","author":"Feinberg","year":"2004","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0525","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/0008-5472.CAN-07-2538","article-title":"The promyelocytic leukemia zinc finger\u2013MicroRNA-221\/-222 pathway controls melanoma progression through multiple oncogenic mechanisms","volume":"68","author":"Felicetti","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0530","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1993-3","article-title":"Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self-poisoning","volume":"18","author":"Ferrey","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0535","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0540","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.wnf.0000154221.37887.73","article-title":"Psychotropic drug interactions with valproate","volume":"28","author":"Fleming","year":"2005","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0545","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.28981","article-title":"Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients","volume":"121","author":"Fleming","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108301_bb0550","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ijc.32172","article-title":"High response rates for T-VEC in early metastatic melanoma (stage IIIB\/C-IVM1a)","volume":"145","author":"Franke","year":"2019","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0555","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/imt.13.108","article-title":"Epigenetics of melanoma: implications for immune-based therapies","volume":"5","author":"Fratta","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0560","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1349-7006.2004.tb03184.x","article-title":"Promoter methylation profiling of 30 genes in human malignant melanoma","volume":"95","author":"Furuta","year":"2004","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0565","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1158\/0008-5472.CAN-06-0157","article-title":"Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas","volume":"66","author":"Furuta","year":"2006","journal-title":"Cancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108301_bib2051","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0570","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ijc.31199","article-title":"HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma","volume":"142","author":"Gallagher","year":"2018","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0575","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-019-0776-0","article-title":"The timeline of epigenetic drug discovery: from reality to dreams","volume":"11","author":"Ganesan","year":"2019","journal-title":"Clinical Epigenetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0585","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0590","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0595","doi-asserted-by":"crossref","first-page":"701","DOI":"10.18632\/genesandcancer.153","article-title":"SIRT6 histone deacetylase functions as a potential oncogene in human melanoma","volume":"8","author":"Garcia-Peterson","year":"2017","journal-title":"Genes & Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0600","first-page":"5355","article-title":"Targeting histone deacetylases in malignant melanoma: A future therapeutic agent or just great expectations?","volume":"37","author":"Garmpis","year":"2017","journal-title":"Anticancer Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108301_bb0605","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.ajpath.2020.07.002","article-title":"Expression of DNA methyltransferase 1 is a hallmark of melanoma, correlating with proliferation and response to B-Raf and mitogen-activated protein kinase inhibition in melanocytic tumors","volume":"190","author":"Gassenmaier","year":"2020","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0610","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jid.2015.12.026","article-title":"Pro-Proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma","volume":"136","author":"George","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0615","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000509879","article-title":"Importance of microRNAs in skin oncogenesis and their suitability as agents and targets for topical therapy","volume":"33","author":"Gerloff","year":"2020","journal-title":"Skin Pharmacology and Physiology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0620","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10495-006-0283-6","article-title":"Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells","volume":"11","author":"Gillespie","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0625","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082048","article-title":"Epigenetic regulation in melanoma: Facts and hopes","volume":"10","author":"Giunta","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0630","first-page":"2989","article-title":"DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer","volume":"33","author":"Gnyszka","year":"2013","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0635","doi-asserted-by":"crossref","first-page":"36711","DOI":"10.18632\/oncotarget.9164","article-title":"RMEL3, a novel BRAF V600E -associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma","volume":"7","author":"Goedert","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0640","first-page":"5336","article-title":"Low frequency of p16\/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors","volume":"57","author":"Gonzalgo","year":"1997","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0645","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4161\/cbt.20558","article-title":"Selenium-containing histone deacetylase inhibitors for melanoma management","volume":"13","author":"Gowda","year":"2012","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0650","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246180","article-title":"Enhancing therapeutic approaches for melanoma patients targeting epigenetic modifiers","volume":"13","author":"Gracia-Hernandez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0655","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/jdv.15363","article-title":"The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma","volume":"33","author":"Graf","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0660","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/cancers5030919","article-title":"Role of hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs) in the treatment of solid malignancies","volume":"5","author":"Grassadonia","year":"2013","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-305","article-title":"Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation","volume":"9","author":"Gravina","year":"2010","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0670","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/bjc.2011.288","article-title":"miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions","volume":"105","author":"Grignol","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0675","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.biochi.2012.07.025","article-title":"DNA methylation inhibitors in cancer: Recent and future approaches","volume":"94","author":"Gros","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0680","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1016\/j.bmcl.2008.07.119","article-title":"Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents","volume":"18","author":"Guandalini","year":"2008","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0685","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejmech.2013.05.017","article-title":"Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring","volume":"66","author":"Guandalini","year":"2013","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0690","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1742-7843.2007.00061.x","article-title":"Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients","volume":"100","author":"Gunes","year":"2007","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0695","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2217\/mmt.15.30","article-title":"Epigenetic markers in melanoma","volume":"2","author":"Guo","year":"2015","journal-title":"Melanoma Management"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0700","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051101","article-title":"HDAC8 activates AKT through upregulating PLCB1 and suppressing DESC1 expression in MEK1\/2 inhibition-resistant cells","volume":"10","author":"Ha","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011574","article-title":"miR-148 regulates mitf in melanoma cells","volume":"5","author":"Haflidad\u00f3ttir","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0710","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0715","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0720","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1021\/acs.jmedchem.7b00176","article-title":"Rational design of bisubstrate-type analogues as inhibitors of DNA methyltransferases in cancer cells","volume":"60","author":"Halby","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108301_bb0725","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108301_bb0730","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/0008-5472.CAN-20-3145","article-title":"LncRNA SAMMSON mediates adaptive resistance to RAF inhibition in BRAF-mutant melanoma cells","volume":"81","author":"Han","year":"2021","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108301_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100090","article-title":"Drugging the epigenome: Overcoming resistance to targeted and immunotherapies in melanoma","volume":"2","author":"Hanly","year":"2021","journal-title":"JID Innovations : Skin Science from Molecules to Population Health"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0740","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaad.2014.01.914","article-title":"Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma","volume":"70","author":"Harcharik","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bib2054","doi-asserted-by":"crossref","first-page":"v559","DOI":"10.1093\/annonc\/mdz255.058","volume":"30","author":"Hassel","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0745","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.biochi.2012.05.007","article-title":"Epigenomics of cancer \u2013 emerging new concepts","volume":"94","author":"Hassler","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0750","doi-asserted-by":"crossref","unstructured":"Haugh, A. M., & Johnson, D. B. (2019). Management of V600E and V600K BRAF-mutant melanoma. Current Treatment Options in Oncology 20, 1\u201316.","DOI":"10.1007\/s11864-019-0680-z"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0755","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2019.10.033","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receivingdabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials","volume":"125","author":"Hauschild","year":"2020","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0760","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/sj.onc.1206445","article-title":"Genetics of melanoma predisposition","volume":"22","author":"Hayward","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0765","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/0008-5472.CAN-11-1977","article-title":"Tumor suppressive microRNAs miR-34a\/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D","volume":"72","author":"Heinemann","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0770","doi-asserted-by":"crossref","unstructured":"Heinemann, A., Cullinane, C., Paoli-Iseppi, R. de, Wilmott, J. S., Gunatilake, D., Madore, J., et al. (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget 6, 21507\u201321521.","DOI":"10.18632\/oncotarget.4242"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0775","doi-asserted-by":"crossref","unstructured":"Helmbold, P., Richter, A. M., Walesch, S., Skorokhod, A., Marsch, W. C., Enk, A., & Dammann, R. H. (2012). RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. The Journal of Investigative Dermatology, 132, 687\u2013694.","DOI":"10.1038\/jid.2011.380"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0780","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020849","article-title":"HDAC2 is involved in the regulation of BRN3A in melanocytes and melanoma","volume":"23","author":"Heppt","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108301_bb0790","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2022.108301_bib2046","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108301_bb0795","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0800","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1038\/sj.onc.1207505","article-title":"Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients","volume":"23","author":"Hoon","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0805","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/jid.2012.36","article-title":"AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome","volume":"132","author":"Hoshimoto","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0810","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/107327480901600302","article-title":"Epigenetics in human melanoma","volume":"16","author":"Howell","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0815","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2017.08.069","article-title":"Targeting breast cancer stem cells by novel HDAC3-selective inhibitors","volume":"140","author":"Hsieh","year":"2017","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108301_bb0820","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1172\/JCI98060","article-title":"Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma","volume":"128","author":"Huber","year":"2018","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0825","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/CAD.0b013e3283300a0f","article-title":"A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways","volume":"20","author":"Hwang","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0830","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/cam4.862","article-title":"A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma","volume":"5","author":"Ibrahim","year":"2016","journal-title":"Cancer Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108301_bb0835","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0840","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/fon-2018-0659","article-title":"Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival","volume":"15","author":"Indini","year":"2019","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-020-01394-6","article-title":"Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies","volume":"20","author":"Javanmard","year":"2020","journal-title":"Cancer Cell International"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108301_bb0850","first-page":"2117","article-title":"PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab","volume":"6","author":"Jazirehi","year":"2016","journal-title":"American Journal of Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0855","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.acthis.2011.11.001","article-title":"The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma","volume":"114","author":"Jiang","year":"2012","journal-title":"Acta Histochemica"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108301_bb0860","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/imt.15.35","article-title":"Talimogenelaherparepvec (T-VEC) for the treatment of advanced melanoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0865","doi-asserted-by":"crossref","unstructured":"Jones, P. A., Issa, J. P. J., & Baylin, S. (2016). Targeting the cancer epigenome for therapy. Nature Reviews Genetics 17, 630\u2013641.","DOI":"10.1038\/nrg.2016.93"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0870","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature23451","article-title":"Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood","volume":"548","author":"Joung","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0875","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Oncotargets and Therapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0880","first-page":"51","article-title":"HDAC2 inhibitor valproic acid increases radiation sensitivity of drug-resistant melanoma cells","volume":"7","author":"Kalal","year":"2019","journal-title":"Medical Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108301_bib2052","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02242-4","article-title":"Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors","volume":"9","author":"Kalin","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0885","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2010.12.010","article-title":"The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker","volume":"61","author":"Kanemaru","year":"2011","journal-title":"Journal of Dermatological Science"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0890","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","article-title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial","volume":"18","author":"Kantarjian","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0895","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1535-7163.MCT-06-0125","article-title":"Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma","volume":"6","author":"Kato","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0900","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jdermsci.2014.04.014","article-title":"Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells","volume":"75","author":"Kato","year":"2014","journal-title":"Journal of Dermatological Science"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108301_bb0905","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Keilholz","year":"2020","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0910","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.gde.2017.03.015","article-title":"The promise of epigenetic therapy: reprogramming the cancer epigenome","volume":"42","author":"Kelly","year":"2017","journal-title":"Current Opinion in Genetics & Development"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0915","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1200\/JCO.2017.35.15_suppl.9547","article-title":"A phase I trial of panobinostat with ipilimumab in advanced melanoma","volume":"35","author":"Khushalani","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0920","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicological Sciences: An Official Journal of the Society of Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0925","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"American Journal of Translational Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108301_bb0930","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0935","doi-asserted-by":"crossref","first-page":"25957","DOI":"10.1074\/jbc.M109.095950","article-title":"Cancer\/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs","volume":"285","author":"Kim","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0940","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-18-2331","article-title":"MITF expression predicts therapeutic vulnerability to p300 inhibition in human melanoma","volume":"79","author":"Kim","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0945","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells","volume":"9","author":"Knox","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0950","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1750-3639.2003.tb00017.x","article-title":"Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas","volume":"13","author":"Komine","year":"2003","journal-title":"Brain Pathology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0955","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/exd.14047","article-title":"DNA hypermethylation is associated with invasive phenotype of malignant melanoma","volume":"29","author":"Koroknai","year":"2020","journal-title":"Experimental Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0960","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0965","first-page":"3124","article-title":"Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2\u2019-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice","volume":"9","author":"Kozar","year":"2003","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0970","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-15-2680","article-title":"Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance","volume":"76","author":"Krumm","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0975","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CMR.0b013e32835d5d6f","article-title":"JARID1B expression in human melanoma and benign melanocytic skin lesions","volume":"23","author":"Kua\u017abicki","year":"2013","journal-title":"Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0980","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PPO.0b013e31824b436e","article-title":"Targeting mutant BRAF in melanoma: Current status and future development of combination therapy strategies","volume":"18","author":"Kudchadkar","year":"2012","journal-title":"Cancer Journal"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0985","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"70","author":"Kulis","year":"2010","journal-title":"Advances in Genetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0990","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/jid.2014.50","article-title":"SIRT1 regulates lamellipodium extension and migration of melanoma cells","volume":"134","author":"Kunimoto","year":"2014","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb0995","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00728-w","article-title":"Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma","volume":"18","author":"Kunz","year":"2020","journal-title":"Journal of Nanobiotechnology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1000","first-page":"4163","article-title":"The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel","volume":"27","author":"Kuwajima","year":"2007","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1005","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2217\/fon-2020-0151","article-title":"Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review","volume":"16","author":"Kyriakou","year":"2020","journal-title":"Future Oncology (London, England)"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1010","doi-asserted-by":"crossref","unstructured":"Lahtz, C., Stranzenbach, R., Fiedler, E., Helmbold, P., & Dammann, R. H. (2010). Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. Journal of Investigative Dermatology 130, 620\u2013622.","DOI":"10.1038\/jid.2009.226"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1015","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1038\/cddis.2013.192","article-title":"Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3","volume":"4","author":"Lai","year":"2013","journal-title":"Cell Death & Disease"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108301_bb1020","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.21873\/anticanres.15828","article-title":"Valproic acid enhances radiosensitization via DNA double-strand breaks for boronophenylalanine-mediated neutron capture therapy in melanoma cells","volume":"42","author":"Lai","year":"2022","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-019-0517-0","article-title":"HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics","volume":"7","author":"Laino","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"20","key":"10.1016\/j.pharmthera.2022.108301_bb1030","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108301_bb1035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"16","key":"10.1016\/j.pharmthera.2022.108301_bb1040","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108301_bb1045","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1634\/theoncologist.2014-0429","article-title":"Adjusting for the confounding effects of treatment switching-the BREAK-3 trial: Dabrafenib versus dacarbazine","volume":"20","author":"Latimer","year":"2015","journal-title":"The Oncologist"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058267","article-title":"Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells","volume":"8","author":"Laurenzana","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108301_bb1055","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.3390\/cancers12113378","article-title":"The non-coding landscape of cutaneous malignant melanoma: A possible route to efficient targeted therapy","volume":"12","author":"Laz\u0103r","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108301_bb1065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jid.2020.06.038","article-title":"MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAFV600E-driven melanoma growth in vivo and BRAF\/MEK inhibitor resistance","volume":"141","author":"Lee","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661737","article-title":"Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: Implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma","volume":"12","author":"Lelliott","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1075","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines","volume":"99","author":"Leoni","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/pcmr.12537","article-title":"The emerging role of long non-coding RNAs in cutaneous melanoma","volume":"29","author":"Leucci","year":"2016","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature17161","article-title":"Melanoma addiction to the long non-coding RNA SAMMSON","volume":"531","author":"Leucci","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the treatment of valproic acid-induced toxicity","volume":"47","author":"Lheureux","year":"2009","journal-title":"Clinical Toxicology (Philadelphia, Pa.)"},{"issue":"37","key":"10.1016\/j.pharmthera.2022.108301_bb1095","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41388-018-0172-9","article-title":"Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression","volume":"22","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1100","article-title":"MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1586\/edm.13.4","article-title":"Diagnostic implications of loss of 5-hydroxymethylcytosine for melanoma","volume":"8","author":"Lian","year":"2013","journal-title":"Expert Review of Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1110","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.27.1_supplement.1088.15","article-title":"Inhibition of lysine-specific histone demethylase LSD1 suppresses melanoma growth","volume":"27","author":"Lian","year":"2013","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1115","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2015.08.005","article-title":"DNA methylation inhibitors in cancer therapy: The immunity dimension","volume":"162","author":"Licht","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jgm.1036","article-title":"Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines","volume":"9","author":"Lillehammer","year":"2007","journal-title":"The Journal of Gene Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2017.01.004","article-title":"Clinical and biological effects of demethylating agents on solid tumours - A systematic review","volume":"54","author":"Linnekamp","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1755-148X.2008.00484.x","article-title":"Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling","volume":"21","author":"Liu","year":"2008","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0753-0","article-title":"Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells","volume":"14","author":"Liu","year":"2016","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1145","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0765-5","article-title":"Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer","volume":"17","author":"Liu","year":"2018","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1150","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/1535-7163.MCT-18-0395","article-title":"KDM5B promotes drug resistance by regulating melanoma-propagating cell subpopulations","volume":"18","author":"Liu","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1155","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-021-01046-0","article-title":"Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy","volume":"13","author":"Lodewijk","year":"2021","journal-title":"Clinical Epigenetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1160","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1165","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1170","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1175","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.3779","article-title":"SWI\/SNF complex in cancer","volume":"49","author":"Lu","year":"2017","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1180","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/jm0303655","article-title":"Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors","volume":"47","author":"Lu","year":"2004","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1185","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jid.2016.08.024","article-title":"Combining type I interferons and 5-Aza-2\u2032-deoxycitidine to improve anti-tumor response against melanoma","volume":"137","author":"Lucarini","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"10336","key":"10.1016\/j.pharmthera.2022.108301_bb1190","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1195","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/jid.2012.357","article-title":"MiR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes","volume":"133","author":"Luo","year":"2013","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1205","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/jnci\/dji311","article-title":"DNA methyltransferase inhibitors and the development of epigenetic cancer therapies","volume":"97","author":"Lyko","year":"2005","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108301_bb1210","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0040-1709126","article-title":"Targeted therapy and traditional chemotherapy in melanoma and cutaneous squamous cell carcinoma","volume":"36","author":"Ma","year":"2020","journal-title":"Facial Plastic Surgery : FPS"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1215","article-title":"Early response assessment in advanced stage melanoma treated with combination ipilimumab\/nivolumab","volume":"13","author":"Ma","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1220","doi-asserted-by":"crossref","unstructured":"Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., et al. (2019). MAPK pathway suppression unmasks latent dna repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1 -mutant melanomas. Cancer Discovery 9, 526\u2013545.","DOI":"10.1158\/2159-8290.CD-18-0879"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/B978-0-12-380866-0.60012-5","article-title":"DNA Demethylating Agents and Epigenetic Therapy of Cancer","volume":"70","author":"Mani","year":"2010","journal-title":"Advances in Genetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1230","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/mc.22542","article-title":"MicroRNA-21 regulates the ERK\/NF-\u03baB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN","volume":"56","author":"Mao","year":"2017","journal-title":"Molecular Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1235","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.jid.5700073","article-title":"Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma","volume":"126","author":"Marini","year":"2006","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1240","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018762","article-title":"Writers and Readers of Histone Acetylation: Structure, Mechanism, and Inhibition","volume":"6","author":"Marmorstein","year":"2014","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1245","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1021\/jm400634n","article-title":"Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit","volume":"56","author":"Marson","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1250","first-page":"209","article-title":"Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance","volume":"3","author":"Martinez-Card\u00fas","year":"2015","journal-title":"Annals of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1255","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/fon.14.252","article-title":"Vemurafenib for the treatment of BRAF mutant metastatic melanoma","volume":"11","author":"Martin-Liberal","year":"2015","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1260","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2217\/epi.15.77","article-title":"Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives","volume":"7","author":"Marzese","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/0008-5472.CAN-18-1397","article-title":"miR-146a Controls Immune Response in the Melanoma Microenvironment","volume":"79","author":"Mastroianni","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1270","doi-asserted-by":"crossref","first-page":"349","DOI":"10.21873\/cgp.20094","article-title":"Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A","volume":"15","author":"Mazzio","year":"2018","journal-title":"Cancer Genomics & Proteomics"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108301_bb1275","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1280","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0560.2006.00678.x","article-title":"Expression of polycomb group protein EZH2 in nevi and melanoma","volume":"34","author":"McHugh","year":"2007","journal-title":"Journal of Cutaneous Pathology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105115","article-title":"Resistance to Targeted Therapy and RASSF1A loss in melanoma: What are we missing?","volume":"22","author":"McKenna","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1290","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202050852","article-title":"Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation","volume":"22","author":"Melixetian","year":"2021","journal-title":"EMBO Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1295","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030577","article-title":"Regulation of LncRNAs in melanoma and their functional roles in the metastatic process","volume":"11","author":"Melixetian","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108301_bb1300","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11864-022-00946-4","article-title":"Targeted therapy for melanomas without BRAF V600 mutations","volume":"23","author":"Menzer","year":"2022","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1305","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nsmb.2480","article-title":"Structure and function of long noncoding RNAs in epigenetic regulation","volume":"20","author":"Mercer","year":"2013","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1310","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.4161\/15592294.2014.983361","article-title":"RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells","volume":"9","author":"Mezzanotte","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1315","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.drudis.2015.01.007","article-title":"Histone deacetylases: Structural determinants of inhibitor selectivity","volume":"20","author":"Micelli","year":"2015","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-017-0332-8","article-title":"Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities","volume":"9","author":"Micevic","year":"2017","journal-title":"Clinical Epigenetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1330","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10637-011-9766-6","article-title":"Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination","volume":"30","author":"Millward","year":"2011","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1335","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-06-0384","article-title":"Epigenetic silencing of the PTEN gene in melanoma","volume":"66","author":"Mirmohammadsadegh","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165102","article-title":"Integrated genomics identifies miR-32\/MCL-1 pathway as a critical driver of melanomagenesis: Implications for miR-replacement and combination therapy","volume":"11","author":"Mishra","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108301_bb1345","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00432-018-2726-1","article-title":"Melanoma treatment: from conventional to nanotechnology","volume":"144","author":"Mishra","year":"2018","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1350","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pharmthera.2018.06.001","article-title":"From chemo-prevention to epigenetic regulation: The role of isothiocyanates in skin cancer prevention","volume":"190","author":"Mitsiogianni","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108301_bb1355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21124544","article-title":"MicroRNAs as key players in melanoma cell resistance to MAPK and immune checkpoint inhibitors","volume":"21","author":"Motti","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1360","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00569","article-title":"LNMAT1 promotes invasion-metastasis cascade in malignant melanoma by epigenetically suppressing CADM1 expression","volume":"9","author":"Mou","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1365","article-title":"The histone demethylase PHF8 regulates TGF\u03b2 signaling and promotes melanoma metastasis","volume":"8","author":"Moubarak","year":"2022","journal-title":"Advances"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/biom8020021","article-title":"Circulating MicroRNA biomarkers in melanoma: Tools and challenges in personalised medicine","volume":"8","author":"Mumford","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3046-6","article-title":"Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis","volume":"17","author":"Murahari","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1380","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/sj.jid.5701216","article-title":"Transcriptional modulation using HDACidepsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma","volume":"128","author":"Murakami","year":"2008","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1385","first-page":"833","article-title":"Hypomethylation of pericentromeric DNA in breast adenocarcinomas","volume":"77","author":"Narayan","year":"1998","journal-title":"Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/epigenomes1010003","article-title":"New frontiers in melanoma epigenetics\u2014the more we know, the more we don\u2019t know","volume":"1","author":"Nguyen","year":"2017","journal-title":"Epigenomes"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1395","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/imt.11.45","article-title":"Immunomodulatory cytokines as therapeutic agents for melanoma","volume":"3","author":"Nicholas","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1400","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s11095-010-0054-5","article-title":"Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (\u2212)-epigallocatechin-3-gallate (EGCG)","volume":"27","author":"Nihal","year":"2010","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1405","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.18632\/oncotarget.1791","article-title":"SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells","volume":"5","author":"Ohanna","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1410","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.chembiol.2015.03.014","article-title":"Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism","volume":"22","author":"Olson","year":"2015","journal-title":"Chemistry & Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1415","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1002\/ijc.32432","article-title":"Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target","volume":"145","author":"Orouji","year":"2019","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108301_bb1420","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jid.2020.07.010","article-title":"The melanocyte lineage factor miR-211 promotes BRAF V600E inhibitor resistance HHS Public Access","volume":"141","author":"Ostrowski","year":"2021","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1425","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073660","article-title":"Histone deacetylase (HDAC) inhibitors: A promising weapon to tackle therapy resistance in melanoma","volume":"23","author":"Palamaris","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1430","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/ncb3410","article-title":"Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation","volume":"18","author":"Pan","year":"2016","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1435","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/1878-0261.13185","article-title":"Genes regulated by DNA methylation are involved in distinct phenotypes during melanoma progression and are prognostic factors for patients","volume":"16","author":"Papaiz","year":"2022","journal-title":"Molecular Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108301_bb1440","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2018","author":"Pasquali","year":"2018","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1445","doi-asserted-by":"crossref","first-page":"32370","DOI":"10.1073\/pnas.2016158117","article-title":"Mesylphosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency","volume":"117","author":"Patutina","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1450","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-0749.2005.00225.x","article-title":"Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis","volume":"18","author":"Peltonen","year":"2005","journal-title":"Pigment Cell Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1455","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.omto.2021.05.012","article-title":"Non-coding RNAs in melanoma: Biological functions and potential clinical applications","volume":"22","author":"Peng","year":"2021","journal-title":"Molecular Therapy Oncolytics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1460","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1039\/c1pp05144j","article-title":"UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer","volume":"11","author":"Pfeifer","year":"2012","journal-title":"Photochemical & Photobiological Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1465","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/jim-2016-000066","article-title":"LINE-1 hypomethylation and mutational status in cutaneous melanomas","volume":"64","author":"Pramio","year":"2016","journal-title":"Journal of Investigative Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1470","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-022-01291-x","article-title":"Genome-wide promoter methylation profiling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival","volume":"14","author":"Rius","year":"2022","journal-title":"Clinical Epigenetics"},{"issue":"26","key":"10.1016\/j.pharmthera.2022.108301_bb1475","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108301_bb1480","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108301_bb1485","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"10.1016\/j.pharmthera.2022.108301_bb1490","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108301_bb1495","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108301_bb1500","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1505","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ijc.23211","article-title":"RBP2-H1\/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells","volume":"122","author":"Roesch","year":"2008","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1510","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","article-title":"Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells","volume":"23","author":"Roesch","year":"2013","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108301_bb1515","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14712598.2018.1544614","article-title":"Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?","volume":"18","author":"Rothermel","year":"2018","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1520","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1600-0749.2007.00367.x","article-title":"Epigenetic events in malignant melanoma","volume":"20","author":"Rothhammer","year":"2007","journal-title":"Pigment Cell Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1525","doi-asserted-by":"crossref","first-page":"1806957","DOI":"10.1002\/adma.201806957","article-title":"A dual-bioresponsive drug-delivery depot for combination of epigenetic modulation and immune checkpoint blockade","volume":"31","author":"Ruan","year":"2019","journal-title":"Advanced Materials"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1530","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010209","article-title":"Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention","volume":"14","author":"Ruzic","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1535","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2020.104558","article-title":"The critical roles of lncRNAs in the pathogenesis of melanoma","volume":"117","author":"Safa","year":"2020","journal-title":"Experimental and Molecular Pathology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1540","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrm1945","article-title":"Chromatin remodelling: the industrial revolution of DNA around histones","volume":"7","author":"Saha","year":"2006","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1545","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.b16-01025","article-title":"Histone deacetylase inhibitors sensitize murine B16F10 melanoma cells to carbon ion irradiation by inducing G1 phase arrest","volume":"40","author":"Saito","year":"2017","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1550","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1021\/ja074138u","article-title":"Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes","volume":"130","author":"Salisbury","year":"2008","journal-title":"Journal of the American Chemical Society"},{"issue":"14","key":"10.1016\/j.pharmthera.2022.108301_bib2050","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-17-1914","article-title":"BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody","volume":"24","author":"Sanlorenzo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1555","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1560","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031531","article-title":"Epigenetics in the diagnosis and therapy of malignant melanoma","volume":"23","author":"Santourlidis","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1565","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: Past and future","volume":"10","author":"Sarkar","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1570","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/ijc.24960","article-title":"MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma","volume":"126","author":"Satzger","year":"2010","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1575","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/B978-0-12-380866-0.60003-4","article-title":"Histone modifications and cancer","volume":"70","author":"Sawan","year":"2010","journal-title":"Advances in Genetics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1580","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1585","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1590","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CMR.0b013e328338a35a","article-title":"Aberrant DNA methylation in malignant melanoma","volume":"20","author":"Schinke","year":"2010","journal-title":"Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1595","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/ijms20020383","article-title":"Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: Structure\u2013activity relations of new inhibitors of HDAC and\/or Tubulin function","volume":"20","author":"Schmitt","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1600","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/cr.2008.45","article-title":"MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth","volume":"18","author":"Schultz","year":"2008","journal-title":"Cell Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108301_bb1605","first-page":"1413","article-title":"Nivolumab: A review in advanced melanoma","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs 2015 75:12"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1610","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1074\/mcp.M115.053363","article-title":"Quantitative histone mass spectrometry identifies elevated histone H3 lysine 27 (Lys27) trimethylation in Melanoma","volume":"15","author":"Sengupta","year":"2016","journal-title":"Molecular and Cellular Proteomics"},{"issue":"33","key":"10.1016\/j.pharmthera.2022.108301_bb1615","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1620","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1625","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1630","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","article-title":"Interplay between the cancer genome and epigenome","volume":"153","author":"Shen","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1635","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108301_bb1640","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810029","article-title":"Synergistic effect of simultaneous versus sequential combined treatment of histone deacetylase inhibitor valproic acid with etoposide on melanoma cells","volume":"22","author":"Shyu","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-9-78","article-title":"Methylation levels of the \u201clong interspersed nucleotide element-1\u201d repetitive sequences predict survival of melanoma patients","volume":"9","author":"Sigalotti","year":"2011","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1650","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1655","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1660","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/15680096113139990077","article-title":"DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer","volume":"13","author":"Singh","year":"2013","journal-title":"Current Cancer Drug Targets"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1665","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lfs.2017.02.011","article-title":"Towards therapeutic advances in melanoma management: An overview","volume":"174","author":"Singh","year":"2017","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1670","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14656566.2020.1729122","article-title":"An overview of binimetinib for the treatment of melanoma","volume":"21","author":"Specenier","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108301_bb1675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13061430","article-title":"Systemic therapy of metastatic melanoma: On the road to cure","volume":"13","author":"Steininger","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1680","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9440(10)64174-0","article-title":"Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase","volume":"161","author":"Straume","year":"2002","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05966-z","article-title":"SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling","volume":"9","author":"Strub","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1690","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.7150\/thno.36218","article-title":"The \u201cART\u201d of epigenetics in melanoma: From histone \u201calterations, to resistance and therapies.\u201d","volume":"10","author":"Strub","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/423239","article-title":"BRAF in melanoma: Pathogenesis, diagnosis, inhibition, and resistance","volume":"2011","author":"Sullivan","year":"2011","journal-title":"Journal of Skin Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1700","first-page":"1","article-title":"SIRT1 induces epithelial-mesenchymal transition by promoting autophagic degradation of E-cadherin in melanoma cells","volume":"9","author":"Sun","year":"2018","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1705","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1710","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.bmcl.2004.03.063","article-title":"Thiol-based SAHA analogues as potent histone deacetylase inhibitors","volume":"14","author":"Suzuki","year":"2004","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1715","first-page":"775","article-title":"Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma","volume":"8","author":"Swaika","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1720","first-page":"376","article-title":"Cancer epigenetics","volume":"60","author":"Taby","year":"2010","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1725","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3098940","article-title":"Basal cell carcinoma arises from interfollicular layer of epidermis","volume":"2018","author":"Tan","year":"2018","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1730","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-08-1361","article-title":"CpG Island methylator phenotype predicts progression of malignant melanoma","volume":"15","author":"Tanemura","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1735","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/251098","article-title":"Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma","volume":"2013","author":"Tang","year":"2013","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1740","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129736","article-title":"Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review","volume":"1865","author":"Tangella","year":"2021","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1745","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1021\/acsmedchemlett.7b00223","article-title":"Synthesis and pharmacological evaluation of selective histone deacetylase 6 inhibitors in melanoma models","volume":"8","author":"Tavares","year":"2017","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108301_bb1750","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1755","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/CMR.0b013e32832b274e","article-title":"CpG island methylation profiling in human melanoma cell lines","volume":"19","author":"Tellez","year":"2009","journal-title":"Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1760","first-page":"3097","article-title":"Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma","volume":"8","author":"Tian","year":"2015","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1765","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2147\/OTT.S225661","article-title":"Long noncoding RNA X-inactive specific transcript facilitates cellular functions in melanoma via miR-139-5p\/ROCK1 pathway","volume":"13","author":"Tian","year":"2020","journal-title":"Oncotargets and Therapy"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1770","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1021\/acs.jmedchem.0c00230","article-title":"Achiral derivatives of hydroxamate AR-42 potently inhibit class i HDAC enzymes and cancer cell proliferation","volume":"63","author":"Tng","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1775","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejps.2018.08.030","article-title":"Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects","volume":"124","author":"Trivedi","year":"2018","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1780","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105046","article-title":"Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity","volume":"138","author":"Trivedi","year":"2019","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1785","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17512433.2019.1570847","article-title":"Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations","volume":"12","author":"Trojaniello","year":"2019","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1790","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3389\/fimmu.2020.01228","article-title":"Targeting nuclear LSD1 to reprogram cancer cells and reinvigorate exhausted T cells via a novel LSD1-EOMES switch","volume":"11","author":"Tu","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"22","key":"10.1016\/j.pharmthera.2022.108301_bb1795","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/sj.onc.1206444","article-title":"Melanoma etiology: where are we?","volume":"2003","author":"Tucker","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1800","doi-asserted-by":"crossref","first-page":"4","DOI":"10.29245\/2578-3009\/2019\/1.1165","article-title":"A review of exosomes and their role in the tumor microenvironment and host-tumor \u201cmacroenvironment.\u201d","volume":"3","author":"Tung","year":"2019","journal-title":"Journal of Immunological Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1805","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/mmt-2016-0018","article-title":"Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy","volume":"4","author":"Tyrell","year":"2017","journal-title":"Melanoma Management"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1810","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3892\/or.2016.5340","article-title":"ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation","volume":"37","author":"Ueihuei","year":"2017","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1815","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2174\/1568009611313080004","article-title":"Signal transduction in human cutaneous melanoma and target drugs","volume":"13","author":"Uzdensky","year":"2013","journal-title":"Current Cancer Drug Targets"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1820","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jm4012627","article-title":"Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells","volume":"57","author":"Valente","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1825","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbcan.2012.03.011","article-title":"Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune","volume":"1826","author":"van den Hurk","year":"2012","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1830","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/ijms21030878","article-title":"The miRNAs role in melanoma and in its resistance to therapy","volume":"21","author":"Varrone","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1835","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/pcmr.12049","article-title":"Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells","volume":"26","author":"Venza","year":"2013","journal-title":"Pigment Cell & Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1840","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3892\/or.2016.4618","article-title":"DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma","volume":"35","author":"Venza","year":"2016","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1845","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.18632\/oncotarget.6599","article-title":"Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b","volume":"7","author":"Vergani","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108301_bb1850","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126388","article-title":"The treatment of advanced melanoma: Therapeutic update","volume":"23","author":"Villani","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1855","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-008-0067-y","article-title":"Melanoma and the tumor microenvironment","volume":"10","author":"Villanueva","year":"2008","journal-title":"Current Oncology Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1860","first-page":"4984","article-title":"Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells","volume":"63","author":"Villar-Garea","year":"2003","journal-title":"Cancer Research"},{"issue":"15","key":"10.1016\/j.pharmthera.2022.108301_bb1865","doi-asserted-by":"crossref","first-page":"25395","DOI":"10.18632\/oncotarget.15915","article-title":"Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells","volume":"8","author":"Vitiello","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1870","doi-asserted-by":"crossref","first-page":"248","DOI":"10.18632\/oncoscience.443","article-title":"Biological role of miR-204 and miR-211 in melanoma","volume":"5","author":"Vitiello","year":"2018","journal-title":"Oncoscience"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1875","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1254\/jphs.FPJ04055X","article-title":"Roles of SIRT1 and phosphoinositide 3-OH kinase\/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death","volume":"97","author":"Wang","year":"2005","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1880","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/acschembio.2c00062","article-title":"Exploring methods of targeting histone methyltransferases and their applications in cancer therapeutics","volume":"17","author":"Wang","year":"2022","journal-title":"ACS Chemical Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108301_bb1885","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1890","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbcan.2010.03.003","article-title":"Genome-wide hypomethylation in cancer may be a passive consequence of transformation","volume":"1806","author":"Wild","year":"2010","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1895","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.4161\/15384101.2014.949085","article-title":"Sirtuin deacetylases: A new target for melanoma management","volume":"13","author":"Wilking","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1900","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/15384101.2017.1288323","article-title":"Expression profile of SIRT2 in human melanoma and implications for sirtuin-based chemotherapy","volume":"16","author":"Wilking-Busch","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1905","series-title":"Cutaneous Melanoma: Etiology and Therapy","year":"2017"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1910","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","article-title":"Chemotherapy for melanoma","volume":"167","author":"Wilson","year":"2016","journal-title":"Cancer Treatment and Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1915","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/icb.2011.96","article-title":"Modulation of antigen-presenting cells by HDAC inhibitors: Implications in autoimmunity and cancer","volume":"90","author":"Woan","year":"2012","journal-title":"Immunology and Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1920","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","article-title":"The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity","volume":"23","author":"Woods","year":"2013","journal-title":"Melanoma Research"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1925","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1038\/sj.onc.1207647","article-title":"Genetic and epigenetic alterations of the APC gene in malignant melanoma","volume":"23","author":"Worm","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1930","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194848","article-title":"The functional role of long non-coding RNAs in Melanoma","volume":"13","author":"Wozniak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1935","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-020-01239-2","article-title":"LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21\/E-cadherin axis","volume":"20","author":"Wu","year":"2020","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1940","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00280-014-2501-1","article-title":"Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)","volume":"74","author":"Xia","year":"2014","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2017.03.038","article-title":"Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents","volume":"134","author":"Xie","year":"2017","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1950","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejmech.2017.08.041","article-title":"Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents","volume":"143","author":"Xie","year":"2018","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1955","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s13277-015-4599-0","article-title":"Circulating epigenetic biomarkers in melanoma","volume":"37","author":"Xin","year":"2015","journal-title":"Tumor Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1960","article-title":"Role of epigenetic regulation in plasticity of tumor immune microenvironment","volume":"12","author":"Yang","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1965","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1970","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1039\/C9RA02985K","article-title":"Next-generation of selective histone deacetylase inhibitors","volume":"9","author":"Yang","year":"2019","journal-title":"RSC Advances"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1975","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201900427","article-title":"The development process: From SAHA to hydroxamate HDAC inhibitors with branched CAP region and linear linker","volume":"17","author":"Yang","year":"2020","journal-title":"Chemistry & Biodiversity"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1980","article-title":"The JMJD family histone demethylases in crosstalk between inflammation and cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1985","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fcell.2020.00486","article-title":"Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma","volume":"8","author":"Yeon","year":"2020","journal-title":"Frontiers in Cell and Development Biology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb1990","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/jcp.22568","article-title":"RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression","volume":"226","author":"Yi","year":"2011","journal-title":"Journal of Cellular Physiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108301_bb1995","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12457","article-title":"Long non-coding RNAs in melanoma","volume":"51","author":"Yu","year":"2018","journal-title":"Cell Proliferation"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2000","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12506","article-title":"CASC2: An emerging tumour-suppressing long noncoding RNA in human cancers and melanoma","volume":"51","author":"Yu","year":"2018","journal-title":"Cell Proliferation"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ccell.2018.01.002","article-title":"Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma","volume":"33","author":"Yu","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3390\/ijms20040945","article-title":"Hydroxamic acid-based histone deacetylase (HDAC) inhibitors bearing a pyrazole scaffold and a cinnamoyl linker","volume":"20","author":"Zagni","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2015","doi-asserted-by":"crossref","first-page":"89182","DOI":"10.18632\/oncotarget.21269","article-title":"Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study","volume":"8","author":"Zakharia","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114419","article-title":"Targeting EZH2 for cancer therapy: From current progress to novel strategies","volume":"238","author":"Zeng","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0006-2952(03)00509-4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis","volume":"66","author":"Zhang","year":"2003","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2030","first-page":"1","article-title":"MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1\/\u03b2-catenin pathway","volume":"5","author":"Zhang","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2035","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/jcb.26455","article-title":"Retracted: MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study","volume":"119","author":"Zhang","year":"2018","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108301_bb2045","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Reports"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:33:38Z","timestamp":1759012418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822001954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":411,"alternative-id":["S0163725822001954"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108301","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108301"}}